Long-term follow-up from a compassionate use program shows that Jakafi (ruxolitinib) can deliver lasting improvements in quality of life for people living with myelofibrosis and other chronic myeloproliferative neoplasms. These results were presented at the presented these results at the 13th Society of Hematologic Oncology (SOHO) 2025 Annual Meeting in Houston, Texas. Patients reported that symptoms like fatigue and spleen discomfort improved quickly—most within just three months of starting ruxolitinib—and these benefits continued over more than a decade of therapy.
In this study, patients were regularly asked about their symptoms and daily functioning using a standardized questionnaire. Improvements in energy, mood, and ability to do daily activities were seen early and maintained throughout the 12-year follow-up. The most noticeable benefits were in reduced fatigue and spleen-related symptoms, but ongoing gains were also observed in general activity and quality of life.
These results confirm that ruxolitinib does more than shrink the spleen and help control symptoms in myelofibrosis—it can provide long-lasting relief and help people feel better overall. The study highlights the value of regular quality of life assessments when managing MF and reinforces ruxolitinib’s role as an important, durable treatment option for these conditions.
Reference:
Mascarenhas JO, et al. Abstract MPN-192, SOHO 2025, 2-7 Sept.
